Integrated molecular and clinical profiling of transformed splenic marginal zone lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective observational project that collects existing coded tumor material (frozen or FFPE) and linked clinical data from institutional biobanks and medical records after ethical approval. Each patient will receive a unique ID code and annotated baseline and follow-up clinical features will be entered into an electronic case report form with quality checks. Molecular profiling will be performed on available diagnostic and transformation-time tumor samples to characterize genetic complexity alongside clinical course and treatments. The combined molecular and clinical dataset aims to define patterns associated with histological transformation and outcomes in t-SMZL.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults aged 18 years or older, regardless of the gender;
2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease);
3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available;
4. Availability of the baseline and follow-up annotations.

Exclusion Criteria:

* None

Where it's running

• Hôpital Saint Louis
  Paris, France Recruiting
• Fondazione IRCCS Policlinico San Matteo
  Pavia, Italy Recruiting
• Hospital Clínic de Barcelona
  Barcelona, Spain Recruiting
• Columbia University
  New York, New York, United States Not yet recruiting
• Universitz Hospitals Leuven
  Leuven, Belgium Not yet recruiting
• Oncology Institute of Southern Switzerland
  Bellinzona, Switzerland Not yet recruiting

Study contacts

• Study coordinator: IELSG Study Coordination Office
• Email: ielsg@ior.usi.ch
• Phone: +41 58 666 7321

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nemtabrutinib plus rituximab for marginal zone lymphoma

  This phase 2 trial tests whether combining nemtabrutinib with rituximab can help people with marginal zone lymphoma.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07583810

• Epcoritamab for newly diagnosed marginal zone lymphoma

  This trial will test whether the antibody drug epcoritamab helps adults who are newly diagnosed with marginal zone lymphoma.

  Recruiting Phase 2 University of Miami · Miami, Florida · NCT06796998

• Evaluating SGR-1505 for treating mature B-cell neoplasms

  This study is testing a new oral medication called SGR-1505 to see if it is safe and effective for people with certain types of B-cell lymphomas that have not responded to other treatments.

  Recruiting at 36 sites Phase 1 Schrödinger, Inc. · Gilbert, Arizona and 35 other locations · NCT05544019

• Treatment using modified T cells for certain types of lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with certain types of lymphoma that haven't responded to other therapies.

  Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT04223765

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Zanubrutinib plus sonrotoclax for relapsed or refractory B‑cell non‑Hodgkin lymphoma in underrepresented racial and ethnic groups

  This phase 1 trial tests whether combining zanubrutinib and sonrotoclax can help adults from underrepresented racial and ethnic groups whose B‑cell non‑Hodgkin lymphoma has returned or not responded to prior treatment.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06859008

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.